

Educational online workshop on

“targeted therapies in genetic cardiomyopathies and heart failure. From molecular mechanisms to therapeutic targets.”

Organizer: **ESC Working Group on Myocardial Function** together with the study group on **Cardiomyopathies of the Heart Failure Association of the ESC.**

Organizing committee:

- ESC WG Myocardial Function: **T. Thum, S. Heymans**
- HFA, Study Group Cardiomyopathies: **P. Seferovic, R. de Boer, S. Heymans**

Moderator: **Thomas Thum**

Every scientific session will have a discussant who receives questions from the audience online and will select a few to discuss with the speakers

Opening and Introduction	Welcome and organizational remarks Cardiomyopathies in the landscape of heart failure: from genetic causes to the treatment options	Petar M. Seferovic (SR), Thomas Thum (DE) Petar M. Seferovic (SR)	9:00-9:15
Session 1	Molecular targets distinct in genetic CMPs (1) Dilated cardiomyopathies: LMNA, TTN, PLN <ul style="list-style-type: none"> • Laminopathies: mechanisms • Laminopathies: ongoing clinical trials & future prospects • Titin truncation-CMP: mechanisms • Titin-CMP: future clinical trials? • Phospholamban: mechanisms • Phospholamban: current and future clinical trials? Discussion – based on questions submitted online	<ul style="list-style-type: none"> • Rudolf de Boer (NL) • Stephane Heymans (NL) • Wolfgang Linke (DE) Discussant: Gerasimos Filippatos (GR)	9:15-10:15
Session 2	Molecular targets distinct in genetic CMPs (2) Hypertrophic cardiomyopathies; MYH7, MYBPC3, TROP <ul style="list-style-type: none"> • MYH7: mechanisms • MYBPC3: mechanisms • TROP: mechanisms Discussion – based on questions submitted online	<ul style="list-style-type: none"> • Roddy Walsh (NL) • Lucie Carrier (DE) Discussant: Jolanda van der Velden (NL)	10:15-10:55

Break / Buffer Time			10:55-11:10
Industry Presentation Spotlights, 3 x 10 min.		3 speakers - TBD	11:10-11:40
Session 3	New disease modelling technologies <ul style="list-style-type: none"> Engineered heart tissue & iPSC <ul style="list-style-type: none"> The technology Experimental data Discussion – based on questions submitted online	<ul style="list-style-type: none"> Thomas Eschenhagen (DE) Lior Gepstein (IL) Discussant: Carlo Gabriele Tocchetti (IT)	11:40-12:20
Session 4	Oligonucleotide therapeutics <ul style="list-style-type: none"> Technology and Targets Preclinical/Clinical data Discussion – based on questions submitted online	<ul style="list-style-type: none"> Thomas Thum (DE) Stefanie Dimmeler (DE) Discussant: Rudolf de Boer (NL)	12:20-13:00
Break / Buffer Time			13:00-13:15
Session 5	Gene correction, targeted delivery approaches (e.g. Cardioregenix consortium) & experimental models <ul style="list-style-type: none"> Crispr-Cas and related technology (AAV and other vectors) <ul style="list-style-type: none"> The technology Experimental data siRNA silencing (e.g. Sanofi) <ul style="list-style-type: none"> The technology Experimental data Discussion – based on questions submitted online	<ul style="list-style-type: none"> Jean-Sebastien Hulot (FR) Christian Kupatt (DE) Ralph Knöll (SE) Discussant: Johannes Backs (DE)	13:15-14:15
Session 2, Reprise	Molecular targets distinct in genetic CMPs (3) <ul style="list-style-type: none"> MYH7s, MYBPC3, TROP: current and future clinical trials cardiac myosin inhibitors : clinical experience Discussion – based on questions submitted online	Christine E. Seidman (US) Discussant: Thomas Thum (DE)	14:15-14:45
Closure	Summary and Farewell	Stéphane Heymans, Rudolf de Boer (NL)	14:45-15:00